Neuroimaging Core

摘要 – ARTFL LEFFTDS 纵向 FTLD：神经影像核心 脑成像在痴呆症研究中发挥着关键作用，包括用于诊断和分期 多种神经退行性疾病和丰富的临床试验研究小组。在最早阶段 神经退行性疾病，当症状尚未出现时，影像学和其他生物标志物可能会 临床试验中唯一可用于量化药物效果的疾病指标，而影像学可能 最终指导使用经批准的治疗方法。该项目的目标是创建一个神经影像核心 ARTFL LEFFTDS 纵向 FTD (ALLFTD) 项目。核心将确保最佳品质和效率， 通过设计和确保忠实应用为该项目收集的大脑图像的创新使用 跨19个临床中心标准化采集协议并促进先进技术的应用 FTLD领域的成像技术。我们将设计最佳利用扫描仪的采集协议 每个研究地点的高级序列功能，并允许跨区域的图像协调 研究。所有扫描以及质量控制信息将通过 神经影像实验室（LONI）。我们将提供创新技术和资源以供理解 MAPT、GRN 或 C9orf72 基因对 FTLD 神经变性的贡献以及可靠的估计 无症状和有症状突变携带者以及患有突变的患者的皮质体积变化 散发性 FTLD，为未来的临床试验做准备。我们将为建立 整个 FTLD 谱中大脑结构变化的地形分布，并与 LONI 合作以维持 图像档案并建立适当的流程，以确保符合道德且高效的数据访问。 神经影像核心将追求以下目标： 1) 建立和维护统一的 MRI 用于 T1、FLAIR、T2、扩散、ASL 灌注和无任务采集和质量控制的采集协议 横跨 19 个参与地点的功能性 MRI 并为研究项目和研究提供 MRI 扫描 社区，同时保护患者的隐私。 2) 操作标准化的质量控制、图像处理 和数据分析程序。 3) 提供经过处理的横截面和纵向数据，包括区域数据 ALLFTD 项目的连续 MRI 上的皮质体积测量和皮质体积的纵向变化 1 和 2，并与研究界共享这些数据。 4) 咨询 ALLFTD 和外部 研究人员并共享研究工具，以方便使用成像数据进行分析。这届的领导 提出的神经影像核心在图像分析和多中心领导方面拥有丰富的经验 成像工作，包括阿尔茨海默病神经影像倡议 (ADNI)，该倡议为 痴呆症的多部位成像研究。这将有助于确保成像活动的顺利进行 ALLFTD。

ABSTRACT – ARTFL LEFFTDS Longitudinal FTLD: NEUROIMAGING CORE Brain imaging has taken on critical roles in dementia research, including its use for diagnosis and staging of multiple neurodegenerative disorders and enrichment of study groups for clinical trials. In the earliest stages of neurodegenerative disease, when symptoms have not yet developed, imaging and other biomarkers may be the only disease indicators that can be used to quantify drug effects in clinical trials, and imaging may ultimately guide use of approved treatments. The goal of this project is to create a neuroimaging core for the ARTFL LEFFTDS Longitudinal FTD (ALLFTD) project. The core will ensure optimal quality and efficient, innovative use of brain images collected for the project by designing and ensuring faithful application of a standardized acquisition protocol across the 19 clinical sites and promoting the application of advanced imaging technology in the FTLD field. We will design acquisition protocols that optimally utilize the scanner capabilities for the advanced sequences at each study site and allow harmonization of images across the study. All scans, along with the quality control information, will be made available to the public through the Laboratory of Neuroimaging (LONI). We will provide innovative technology and resources for understanding the contribution of MAPT, GRN or C9orf72 genes to neurodegeneration in FTLD and reliable estimates of changes in cortical volume in asymptomatic and symptomatic mutation carriers as well as patients with sporadic FTLD, in preparation for future clinical trials. We will provide resources for establishing the topographic distribution of brain structural changes across the FTLD spectrum, and work with LONI to maintain an archive of images and establish appropriate processes to ensure ethical and efficient access to the data. The Neuroimaging Core will pursue the following aims: 1) Establish and maintain a harmonized MRI acquisition protocol for acquisition and quality control of T1, FLAIR, T2, diffusion, ASL-perfusion, and task free functional MRI across 19 participating sites and supply MRI scans for research projects and the research community, while protecting patient confidentiality. 2) Operate a standardized quality control, image processing and data analysis program. 3) Supply processed cross-sectional and longitudinal data including regional cortical volume measurements and longitudinal change in cortical volume on serial MRIs for ALLFTD Projects 1 and 2, and also share these data with the research community. 4) Consult with ALLFTD and outside researchers and share research tools to facilitate use of imaging data for analysis. The leaders of this proposed neuroimaging core have extensive experience with image analysis and leadership of multicenter imaging efforts, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), which set the standard for multisite imaging studies in dementia. This will help to ensure smooth conduct of the imaging activities for ALLFTD.